Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 66

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Duchenne muscular dystrophy

Not recruiting

Study of DYNE-251 safety and effectiveness in patients with Duchenne muscular dystrophy who are candidates for exon 51 skipping treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Fragment Antibody Targeting Human Tfr1 Conjugated To Phosphorodiamidate Morpholino Oligomer
  • Sponsor:Dyne Therapeutics Inc.

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Gouty arthritis+1

Not recruiting

Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Sint Maartenskliniek Stichting

Spinal muscular atrophy

Not recruiting

Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Taldefgrobep Alfa
  • Sponsor:Biohaven Pharmaceuticals Inc.

Osteoarthritis

Not recruiting

Study on Improving Knee Implant Stability in Osteoarthritis Patients Using Denosumab and Zoledronic Acid

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Region Midtjylland

Duchenne muscular dystrophy

Not recruiting

Study on the Effects of Fordadistrogene Movaparvovec for Patients with Duchenne Muscular Dystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Pfizer Inc.

Rheumatoid arthritis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Filgotinib for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Glycogen storage disease type II

Not recruiting

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Not recruiting

Study on the Safety and Effectiveness of Zilucoplan Auto-Injector for Adults with Generalized Myasthenia Gravis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zilucoplan Sodium
  • Sponsor:UCB Biopharma

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.